In a nutshell This study examined the effect of combined radiation and hormone therapy on long-term fatigue. Researchers reported severe fatigue during and up to 4 years after treatment. Men with increased cancer markers and symptoms were more likely to report higher fatigue levels. Some background Radiation therapy and hormone therapy are often...
Read MoreOngoing treatment(s)-Hormonal therapy Posts on Medivizor
Decline in circulating tumor cells during treatment associated with better survival
In a nutshell This study examined the link between circulating tumor cells (CTCs) and treatment outcome in metastatic castration-resistant prostate cancer (mCRPC). Authors reported better survival outcomes for mCRPC patients with a significant decline in CTC count during treatment. Some background Metastatic castration-resistant prostate...
Read MorePotential predictor of treatment outcomes for metastatic castration-resistant prostate cancer
In a nutshell This study analyzed predictors of treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that testosterone levels before treatment can help predict overall survival in men with mCRPC. Some background Hormone therapy is the standard of care for advanced prostate cancer, including...
Read MoreCirculating tumor cells can predict treatment success with docetaxel
In a nutshell This study examined the predictive value of circulating tumor cells (CTCs) during docetaxel (Taxotere) treatment for metastatic castration-resistant prostate cancer (mCRPC). Researchers reported a strong association between CTCs and treatment response to docetaxel. Some background Hormone therapy is the standard of care for advanced...
Read MoreEarly results of an anti-angiogenic drug in treating advanced prostate cancer
In a nutshell This study investigated cabozantinib (Cometriq), an anti-angiogenic drug, in the treatment of advanced and progressing prostate cancer. Researchers report preliminary evidence for cabozantinib in reducing disease progression and cancer pain. Some background Tumors need to be able to grow new blood vessels in order to grow....
Read MorePlatinum-based drugs: A possible strategy when other treatments stop working
In a nutshell This review analyzed platinum-based drugs in the treatment of advanced castration-resistant prostate cancer. While platinum-based drugs were often associated with various side effects, researchers reported moderate to good treatment effectivity in managing advanced prostate cancer. Some background Hormone therapy is the standard...
Read MoreCan tamoxifen reduce the risk of cancer-related mortality?
In a nutshell The authors aimed to determine whether long-term adjuvant (treatment given after the primary treatment) tamoxifen (Nolvadex) can reduce the risk of death by cancer in pre-menopausal women with estrogen-receptor positive (ER+) breast cancer. Long-term adjuvant tamoxifen treatment showed a reduction in the risk of death due to breast...
Read MoreOverview of first-line treatments for advanced prostate cancer
In a nutshell This review evaluated first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). Authors recommend chemotherapy with docetaxel (Taxotere) for mCRPC with high tumor burden or at high risk of rapid progression. Alternative hormonal therapy or chemotherapy may be effective in other cases. Some background...
Read MorePalbociclib for previously treated hormone-dependent breast cancer
In a nutshell The authors aimed to determine whether palbociclib (Ibrance) could help treat women hormone-receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) metastatic (cancer has spread) breast cancer. The addition of palbociclib showed consistent success against breast cancer that had become resistant...
Read MoreCan treatment with palbociclib affect a person’s quality of life?
In a nutshell This study examined the effect of the drug combination, palbociclib (Ibrance) plus fulvestrant (Faslodex) on the quality of life of breast cancer patients. The study concluded that palbociclib plus fulvestrant allowed patients to maintain a good quality of life while experiencing delayed disease progression. Some background...
Read MoreDifferent metabolic side effects across two forms of hormone therapy
In a nutshell This study compared early metabolic changes across different types of androgen deprivation therapy (ADT). Authors reported that some metabolic changes were more pronounced with pharmacological ADT compared to surgical ADT. Some background ADT is a type of hormone therapy commonly used to treat advanced prostate cancer. ADT targets...
Read MoreCombining therapies early in advanced prostate cancer
In a nutshell This review examined the benefit of adding docetaxel (Taxotere) or bisphosphonates to androgen deprivation therapy (ADT) in advanced prostate cancer. Authors reported a significant benefit when combining docetaxel with ADT in advanced metastatic prostate cancer. There is less evidence to suggest an advantage of bisphosphonates plus...
Read More
